Furthermore, in a phase II trial conducted by Farooqui et al., median PFS was not reached in TP53 mutated CLL patients treated with ibrutinib monotherapy after a median follow-up of 35 months (28, 29). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.